Eagle Pharmaceuticals (NASDAQ:EGRX) Downgraded to Hold at StockNews.com

StockNews.com lowered shares of Eagle Pharmaceuticals (NASDAQ:EGRX – Get Rating) from a buy rating to a hold rating in a research note released on Tuesday.

Separately, Piper Sandler lowered their target price on shares of Eagle Pharmaceuticals from $41.00 to $31.00 in a research note on Tuesday.

Eagle Pharmaceuticals Stock Up 0.4 %

Eagle Pharmaceuticals stock opened at $25.62 on Tuesday. Eagle Pharmaceuticals has a 1-year low of $23.87 and a 1-year high of $52.22. The firm’s fifty day simple moving average is $30.48 and its 200-day simple moving average is $31.00. The company has a current ratio of 1.52, a quick ratio of 0.99 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $333.57 million, a P/E ratio of 13.34 and a beta of 0.92.

Institutional Trading of Eagle Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Alliancebernstein L.P. grew its position in Eagle Pharmaceuticals by 10.1% in the 4th quarter. Alliancebernstein L.P. now owns 43,534 shares of the specialty pharmaceutical company’s stock worth $1,272,000 after purchasing an additional 3,978 shares during the last quarter. Point72 Middle East FZE acquired a new stake in shares of Eagle Pharmaceuticals during the 4th quarter valued at about $53,000. State of Tennessee Treasury Department boosted its position in shares of Eagle Pharmaceuticals by 4.1% during the 4th quarter. State of Tennessee Treasury Department now owns 8,345 shares of the specialty pharmaceutical company’s stock valued at $244,000 after acquiring an additional 328 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Eagle Pharmaceuticals during the 4th quarter valued at about $627,000. Finally, Lazard Asset Management LLC boosted its position in shares of Eagle Pharmaceuticals by 8.6% during the 4th quarter. Lazard Asset Management LLC now owns 4,703 shares of the specialty pharmaceutical company’s stock valued at $137,000 after acquiring an additional 373 shares in the last quarter. 88.09% of the stock is currently owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Company Profile

(Get Rating)

Eagle Pharmaceuticals, Inc is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L.